NCT07236502 · Medical College of Wisconsin
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
(MFM)
What this study is about
The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns.
View original scientific description
The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are: Do improvements in eating and exercise patterns lead to improved physical function, quality of life and blood biomarkers of biologial aging among individuals with multiple myeloma? Participants will complete study activities 3-4 times during the study. 1. In-person assessment to measure physical function, height/weight, body composition, and includes a blood draw 2.
Interventions
BEHAVIORAL
Immediate intervention
16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health
OTHER
Waitlist
Participants will be asked to maintain their behavior over the 16 week waitlist period and will receive weekly text message relating positive messages unrelated to lifestyle
Primary outcome measures
Examine the efficacy of the intervention in producing post-intervention changes in performance-based physical function
Time frame: Baseline, Week 16, Week 32, Week 48
Changes in performance-based physical function between the interventional and control groups will be measured using the Short Physical Performance Battery (SPPB), which comprises a 4-meter walk test to assess gait speed, sit-to-stand test to assess lower body strength, and standing balance tests to assess balance. Scoring for the SPPB ranges from 0 to 12; higher scores indicate higher function.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Adult (≥ 18 years)
- Diagnosed with MM at least one year prior to study enrollment
- Has access to a cell phone
- Be deemed "clinically stable" by their physician guided by the following:
- no near-term changes in planned myeloma-directed therapy anticipated. (e.g., patient who is 3 months from autologous stem cell transplant just starting on maintenance lenalidomide is eligible since maintenance is planned therapy following transplant)
- no new significant myeloma symptoms (e.g., fractures) meriting changes in anti-neoplastic therapies; AND
- stable performance status (ECOG 0-2)
- No reports of severe pain \> Grade 3 \[defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)\].
- Able to participate in moderate PA and strength training per clinician approval and confirmed by participant
- Able to understand and willing to sign a written informed consent document
- English proficient for reading and writing
Exclusion criteria
- Individuals with \<6 months of life anticipated, coexistent amyloidosis, and/or receiving appetite stimulants will not be approached
- Fully adherent to the ACS nutrition and physical activity guidelines
- Currently pregnant or lactating, or anticipating pregnancy
- On another interventional clinical trial that precludes co-enrollment
- Psychiatric or other clinical conditions that preclude study compliance
- Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician
Where
- Maywood, Illinois
- Milwaukee, Wisconsin
Collaborators
National Cancer Institute (NCI), Loyola University Chicago
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 22, 2026 · Source of record for eligibility and locations